
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp demonstrates a positive outlook due to its expected cash-flow positivity and profitability arriving sooner than anticipated, aided by disciplined selling, general, and administrative expenses (SG&A), improved gross margins, and an efficient specialty-pharmacy model that enhances operational leverage. The company has reported strong early launch metrics for its product YUTREPIA, highlighting sustained referral momentum, growing prescriber adoption, and broad payer access, indicating a healthy market presence. Additionally, the management's innovative "white-glove" access model has achieved a notable 75% pull-through rate, reflecting effective patient conversion and adherence, which could further bolster revenue growth.
Bears say
Liquidia Corp faces significant investor concerns regarding the potential approval of sotatercept, which could reduce the demand for its existing prostacyclin-based therapies, thereby impacting revenue projections for its product YUTREPIA. The company may struggle to achieve peak commercial revenue estimates due to factors such as market size, penetration rates, and pricing, which could adversely affect its financial outlook. Furthermore, Liquidia is operating in a highly competitive environment, and any failures in clinical trials or negative safety signals could lead to substantial decreases in asset value and increased volatility of the stock.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares